Biotechnology

Inventiva SA

Inventiva SA released FY2025 earnings on March 30 After-Market EST, actual revenue USD 7.79 M (forecast USD 10.05 M), actual EPS USD -2.1843 (forecast USD -2.1164)

Inventiva SA released FY2025 Q3 earnings on March 30 After-Market EST, actual revenue USD 674.91 K (forecast USD 10.17 M), actual EPS USD -0.3947 (forecast USD -0.52)

Inventiva SA released FY2025 Q4 earnings on March 30 After-Market EST, actual revenue USD 675.95K, actual EPS USD -0.3953

Inventiva SA released FY2025 9 Months earnings on March 30 After-Market EST, actual revenue USD 7.678 M, actual EPS USD -2.2169

Inventiva SA to Release FY2025 Earnings on March 30 After-Market EST, Forecast Revenue USD 12.05 M, EPS USD -2.1164

Inventiva SA to Release FY2025 Q3 Earnings on November 21 After-Market EST, Forecast Revenue USD 10.05 M, EPS USD -0.52

Inventiva SA to Present New Clinical Data on Lanifibranor at AASLD Liver Meeting

Inventiva SA released FY2025 Q1 earnings on September 29 (EST), actual revenue USD 3.036 M, actual EPS USD -0.8746

Inventiva SA released FY2025 Q2 earnings on September 29 (EST), actual revenue USD 3.283M, actual EPS USD -0.9481

Inventiva SA released FY2025 Semi-Annual Earnings on September 29 After-Market EST, actual revenue USD 6.32 M (forecast USD 5.267 M), actual EPS USD -1.8204 (forecast USD -0.6365)

Inventiva SA to Release FY2025 Semi-Annual Earnings on September 29, 2025 (EST), Forecast Revenue USD 5.322 M, EPS USD -0.6365

Inventiva Receives 10 Million Dollar Milestone Payment from CTTQ

Inventiva SA lanifibranor Phase 2b trial results positive

Inventiva Releases Lanifibranor Corporate Presentation

Inventiva SA reports Q1 2025 no revenue and announces layoffs

Inventiva SA Signs Repurchase Agreement at 40 Euros Per Share

Inventiva SA released FY2024 9 Months Earnings on March 26, 2025 (EST) with actual revenue of USD 9.282 M and EPS of USD -2.1309

Inventiva SA released FY2024 Q3 earnings on March 26 (EST), actual revenue USD 6.343 M (forecast USD 1.502 M), actual EPS USD -1.1168

Inventiva SA released FY2024 earnings on March 26 After-Market EST, actual revenue USD 15.17 M (forecast USD 6.977 M), actual EPS USD -3.3157 (forecast USD -1.8095)

Inventiva SA released FY2024 Q4 earnings on March 26 After-Market EST, actual revenue USD 5.909 M (forecast USD 1.491 M), actual EPS USD -1.0403

OPTIMI HEALTH CORP

HCW Biologics

Silexion Therapeutics

Vida Global

GCL Global

BiomX

MetaVia

Micware

MicroAlgo

Inventiva (ENXTPA:IVA) is currently trading at €4.25, facing recent volatility with a 3.41% drop in one day and a 13.44% decline over the past week. Despite this, it has a 1-year total shareholder return of 49.12%. Analysts project a fair value of €10.00, indicating it may be undervalued. However, concerns remain about potential underperformance in clinical trials and ongoing losses. Investors are encouraged to assess risks and rewards before making decisions.

Simplywall

Assessing Inventiva (ENXTPA:IVA) Valuation After Recent Share Price Volatility

PHAR

ATAI

LABU

Analysts highlight three high-risk, high-reward stocks for potential explosive gains: Inventiva (IVA), Pharming Group (PHAR), and Atai Life Sciences (ATAI). Inventiva is focused on lanifibranor, a promising drug for treating nonalcoholic steatohepatitis (NASH), with early Phase III trial data showing positive results. The stock has a Strong Buy consensus rating, and the average price target suggests a 193.3% upside from its current price of $15.75. Investors are encouraged to consider these stocks for significant market opportunities.

Tip Ranks

Pharming Group NV

AtaiBeckley

iShares Global Healthcare

Direxion S&P Biotech Bull 3X

SPDR S&P Biotech

VG Health

3 High-Risk, High-Reward Stocks to Buy Now for Explosive Upside, According to Analysts – 5/8/2026

ARKG

Inventiva (ENXTPA:IVA) has appointed a new leadership team as it prepares for a key Phase 3 data readout. The share price is currently €4.31, reflecting a 6.55% year-to-date return but a 16.15% decline over the past 90 days. Despite a net loss of €354.138 million, the company has strong financial backing, ensuring a cash runway until September 2026. Analysts suggest a fair value of €10.00, indicating the stock is undervalued. However, concerns over losses and auditor flagged risks may challenge this narrative.

Invesco Biotechnology & Genome ETF

First Trust NYSE Arca Biotech Index Fd

VanEck Biotech ETF

iShares Biotechnology ETF

Ark Genomic Revolution ETF

Proshares Ultra Nasdaq Biotech

A Look At Inventiva (ENXTPA:IVA) Valuation As New Leadership Team Prepares For Key Phase 3 Readout

Inventiva (NASDAQ:IVA) experienced a significant increase in trading volume, with 1,311,257 shares traded, up 186% from the previous session. The stock price rose to $5.5150 from $5.01. Analysts have mixed ratings, with Weiss Ratings giving a 'sell' rating, while UBS and others set price targets between $12.00 and $24.00. Institutional investors hold 19.06% of the stock, and the company focuses on developing therapies for metabolic and inflammatory diseases. Despite a current 'Buy' rating, some analysts suggest better investment options.

Market Beat

Inventiva (NASDAQ:IVA) Sees Unusually-High Trading Volume  - Still a Buy?

SBIO

Inventiva SA's Q4 earnings call highlighted strong execution on its pivotal NATiV3 trial for MASH, with enrollment completed in April 2025. The top-line readout is now expected in late 2026, later than anticipated, but management emphasized financial preparedness with EUR 230.9 million in cash. The company is focusing on its lead drug lanifibranor, which has shown promising Phase II results. Despite the extended timeline for results, Inventiva is positioned to navigate the wait, with a significant market opportunity in the underdiagnosed MASH population.

ALPS Medical Breakthrough

Inventiva SA Bets Big on Pivotal MASH Trial

U.S. stock futures rose on Tuesday, with Dow futures up 400 points. However, Phreesia shares plummeted 26.5% in pre-market trading after reporting mixed Q4 results and lowering FY27 sales guidance. Other notable declines included Service Properties Trust down 17.3%, ioneer down 16.2%, and Inventiva down 14.5%. Overall, several stocks experienced significant drops in pre-market trading despite the positive futures outlook.

benzinga_article

Service Properties Trust

Health Care Select Sector SPDR

Phreesia

Ioneer

Direxion S&P Biotech Bear 3X

iShares US Pharma

Innoviva

Phreesia, Service Properties Trust, Inventiva And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session

Inventiva S.A. Sponsored ADR (NASDAQ:IVA) experienced an 18.7% decrease in short interest in March, totaling 447,124 shares. Currently, 0.5% of the stock is sold short, with a short-interest ratio of 1.5 days based on an average daily volume of 296,385 shares. Analysts have mixed ratings, with three Strong Buy, six Buy, and one Sell. The average price target is $16.56. Recently, IVA stock traded down 5.2% to $5.42, with a one-year range of $2.85 to $7.98. Institutional investors hold 19.06% of the stock.

Inventiva S.A. Sponsored ADR (NASDAQ:IVA) Short Interest Update

LifeSci Capital analyst Rami Katkhuda has reaffirmed a Buy rating for Inventiva (IVA) with a price target of $14.00. The analyst consensus for Inventiva is a Strong Buy, with an average price target of $15.50. Katkhuda, who specializes in the Healthcare sector, has an average return of 32.0% and a success rate of 53.85% on his stock recommendations.

LifeSci Capital Sticks to Their Buy Rating for Inventiva (IVA)

LifeSci Capital analyst Rami Katkhuda has maintained a Buy rating on Inventiva, setting a price target of $14.00. His positive outlook is based on lanifibranor's potential in the MASH market, supported by physician sentiment from a survey of 68 specialists. Despite competition, doctors expect to prescribe lanifibranor more frequently, especially if Phase III data confirms its efficacy. The drug's favorable safety profile and potential uptake in specific patient groups further enhance its commercial prospects, despite current cash constraints. Truist Financial also initiated coverage with a Buy rating and a $13.00 price target.

Lanifibranor’s Emerging Role in the MASH Market: Physician Sentiment and Uptake Potential Support a Buy Rating Despite Cash Constraints

Inventiva SA(IVA.US)